Project Grant R21AI193709
Award Date
6/20/25
Completion Date
5/31/27
Dollars Obligated
$421K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $150,000 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Cedars-Sinai Medical Center. The grant supports research to investigate the role of sex differences in immune-stromal cell interactions that drive the development of cardiovascular lesions in Kawasaki disease vasculitis. The research aims to establish the contribution of monocytes, macrophages, neutrophils, and vascular smooth...
This federal Project Grant award, with a total funding of $642,056, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to characterize plasma cell infiltrates in cardiac allograft vasculopathy (CAV), a leading cause of morbidity and mortality after heart transplantation. The key objectives are to: 1) characterize the clonal composition and transcriptome profile...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4,433,050 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cedars-Sinai Medical Center. The grant will fund a 7-year, randomized controlled, double-blind, multicenter clinical trial to determine the effects of pre-implantation, intrarenal artery injection of C1 esterase inhibitor (C1INH) on kidney transplant outcomes for deceased donor kidney transplant recipients. The trial aims...
This Project Grant award of $200,016 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to elucidate the mechanisms by which certain children develop critical illness from SARS-CoV-2 infection. The funded research will: 1) Define and characterize the autoantibody repertoire in children with severe SARS-CoV-2 disease, and 2) Determine the biological consequences of cross-reactivity between SARS-CoV-2 and the host protein...
This Project Grant award for $862,440.00 was made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development and evaluation of a new humanized mouse model to study gene editing therapies targeting chronic hepatitis B virus (HBV) infection. The key objectives are to: 1) Evaluate the anti-HBV efficacy of HBV gene therapy in liver-humanized NSG-PIZ mice, including assessing...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research provides $122,562 over a 4-year period from January 1, 2025 to December 31, 2028. The award supports research to elucidate the mechanisms underlying innate immune activation and recruitment in Leigh syndrome, the most common form of pediatric genetic mitochondrial disease. The research aims to characterize the immune profile of central nervous...
This federal Project Grant award for $892,433.00, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research aimed at understanding the role of eicosanoids (bioactive lipid molecules) in the development of chronic kidney disease (CKD) and associated cardiovascular risk. The research project, led by the principal investigator at Cedars-Sinai Medical Center,...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $561,030 to the Children's Research Institute to study the impact of CD52 knockout on the function of multi-virus-specific T cells. The goal is to determine if CD52 knockout can enable T cell persistence and efficacy in the presence of the immunosuppressive drug alemtuzumab. Key activities include optimizing CRISPR/Cas9 editing of virus-specific T cells,...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $160,518 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Research Institute. The 5-year grant, which began on August 15, 2024, supports the development of the principal investigator into an independent researcher in the field of immune modulation cell therapy for critically ill children, particularly those who have undergone...
This federal Project Grant award, valued at $188,772, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to elucidate the cellular and molecular mechanisms driving macrophage activation syndrome (MAS), a potentially life-threatening hyperinflammatory condition that can occur in patients with rheumatic diseases. The award recipient, the University of Washington,...